aurantio-obtusin has been researched along with 2,6-dihydroxyanthraquinone in 1 studies
| Studies (aurantio-obtusin) | Trials (aurantio-obtusin) | Recent Studies (post-2010) (aurantio-obtusin) | Studies (2,6-dihydroxyanthraquinone) | Trials (2,6-dihydroxyanthraquinone) | Recent Studies (post-2010) (2,6-dihydroxyanthraquinone) |
|---|---|---|---|---|---|
| 24 | 0 | 21 | 24 | 0 | 6 |
| Protein | Taxonomy | aurantio-obtusin (IC50) | 2,6-dihydroxyanthraquinone (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 1.1 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 3.8 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 5.62 | |
| Estrogen receptor beta | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, N; Koyama, J; Morita, I; Nisino, Y; Osakai, T; Tokuda, H | 1 |
1 other study(ies) available for aurantio-obtusin and 2,6-dihydroxyanthraquinone
| Article | Year |
|---|---|
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
Topics: Anthraquinones; Antiviral Agents; Buffers; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Emodin; Herpesvirus 4, Human; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Methylation; Models, Chemical; Virus Activation | 2008 |